Agenda-at-a-Glance

Morning Pre-conferences:
— Advanced Medical Affairs Compliance Issues
— The Basics of Managed Markets
— Medical Device Best Practice Compliance Updates
— Government Programs for the Compliance Officer

Afternoon Opening Plenary Session:
— OIG Compliance Update
— DOJ Evaluation of Corporate Compliance Programs
— DOJ, SEC and FBI FCPA Enforcement Update
— AUSA Roundtable
— Chief Compliance Officer Roundtable
— Networking Reception

Morning Mini Summit Block A:
— Using Behavioral Economics to Improve Compliance Messaging Stickiness
— HCP Engagement: The Road to Proactive Risk Management
— Best Practices for Patient Assistance and Reimbursement Support
— Managed Market Considerations for Hub and Specialty Pharmacy Arrangements
— Compliance and Ethics Consideration in R&D
— Using Data Analytics to Tell the Compliance Effectiveness Story
— International Organization for Standardization (ISO) 37001

Networking Luncheon and Luncheon Mini Summits:
— FDA Regulation and Cutting Edge Technology
— Advancing Compliance: Pulling Critical Levers to Improve Effectiveness
— The Evolution of Compliance Programs after Wells Fargo
— Innovation and Compliance, They are not Mutually Exclusive

Afternoon Mini Summit Block B:
— Third Party Risk Management/Due Diligence Update
— Compliance in the Transactional Context
— Managing an Internal Investigation under CIA, DPA and Data Analytics Failure
— Recent FDA Guidance: Manufacturer Communications and Off-Label Memo
— Small and Mid-Sized Pharma and Device Companies Compliance Considerations
— Advanced Issues in Global Compliance
— Effective and Balanced Monitoring Program based on Risk

Afternoon Mini Summit Block C:
— Advanced Compliance Issues When Contracting with Third Parties
— The Next Generation of Agg Spend Solutions
— Cyber Security for Pharma and Medical Device Companies
— Pricing Considerations (Mylan Epipen, Marathon Pharmaceuticals, et al)
— Optimizing Data Collection for Risk Assessments, Monitoring, and Auditing
— Balancing Risks in Patient and Product Support

Afternoon Closing Plenary Session:
— Role of Behavioral Economics in Ethics and Compliance
— PhRMA Priorities and Policy Initiatives
— Overview of the Policy and Politics of Pharma Pricing
— Rewarding Results: Value-Based Contracting for Biopharmaceuticals